When assessing HER2+ tumors by ER status, patients with ER+/HER2+ tumors and obesity had lower odds of pCR compared with normal weight counterparts (ORadj=0.72 [95%CI = 0.42–1.23]) (Supplementary Table 2). The gene discussed is ERBB2; the disease is obesity due to melanocortin 4 receptor deficiency.